Amicus Therapeutics (NASDAQ:FOLD) Now Covered by BTIG Research

Research analysts at BTIG Research started coverage on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note issued to investors on Monday, FinViz reports. The brokerage set a “buy” rating and a $15.00 price target on the biopharmaceutical company’s stock. BTIG Research’s price target points to a potential upside of 66.11% from the company’s current price.

Several other research analysts also recently commented on FOLD. SVB Leerink reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, June 10th. Chardan Capital reissued a “neutral” rating on shares of Amicus Therapeutics in a report on Thursday, July 1st. Needham & Company LLC initiated coverage on Amicus Therapeutics in a report on Thursday, May 27th. They set a “hold” rating on the stock. Cantor Fitzgerald raised Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a report on Monday, April 19th. Finally, UBS Group initiated coverage on Amicus Therapeutics in a report on Thursday, May 20th. They set a “buy” rating and a $16.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.21.

Shares of Amicus Therapeutics stock traded down $0.13 during trading on Monday, hitting $9.03. 63,215 shares of the stock traded hands, compared to its average volume of 2,264,675. The company has a market capitalization of $2.40 billion, a PE ratio of -9.31 and a beta of 1.12. The company has a current ratio of 5.05, a quick ratio of 4.86 and a debt-to-equity ratio of 1.55. Amicus Therapeutics has a twelve month low of $8.68 and a twelve month high of $25.39. The business’s fifty day moving average is $9.62.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Sunday, May 9th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.01). Amicus Therapeutics had a negative net margin of 95.05% and a negative return on equity of 80.85%. The company had revenue of $66.40 million during the quarter, compared to the consensus estimate of $71.76 million. As a group, analysts forecast that Amicus Therapeutics will post -0.81 earnings per share for the current fiscal year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $10.28, for a total value of $77,100.00. Following the sale, the chief executive officer now owns 884,730 shares in the company, valued at $9,095,024.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lynn Dorsey Bleil bought 28,605 shares of the stock in a transaction dated Tuesday, May 25th. The shares were purchased at an average price of $8.74 per share, for a total transaction of $250,007.70. Following the purchase, the director now owns 50,310 shares of the company’s stock, valued at approximately $439,709.40. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 31,605 shares of company stock valued at $278,268 and have sold 104,913 shares valued at $1,052,618. Corporate insiders own 2.50% of the company’s stock.

Several hedge funds have recently modified their holdings of the business. First Horizon Advisors Inc. bought a new position in shares of Amicus Therapeutics in the 1st quarter worth about $27,000. Harbor Investment Advisory LLC increased its position in Amicus Therapeutics by 76.6% in the 1st quarter. Harbor Investment Advisory LLC now owns 4,670 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 2,026 shares in the last quarter. Lazard Asset Management LLC increased its position in Amicus Therapeutics by 95.5% in the 1st quarter. Lazard Asset Management LLC now owns 5,657 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 2,763 shares in the last quarter. Twin Lakes Capital Management LLC bought a new stake in Amicus Therapeutics in the 1st quarter valued at about $59,000. Finally, Fieldpoint Private Securities LLC acquired a new position in Amicus Therapeutics during the 1st quarter valued at about $71,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates.

Read More: What is the price-to-earnings growth (PEG) ratio?

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.